Anti-β2-Glycoprotein I and Anti-Prothrombin Antibodies in Antiphospholipid-Negative Patients with Thrombosis

Summary

We performed a case-control study to assess whether anti-β2-glycoprotein I and anti-prothrombin antibodies are independent risk factors of thrombosis. Cases were 79 patients with arterial and/or venous thrombosis without lupus anticoagulants, anticardiolipin antibodies and systemic lupus erythematosus; controls were 85 normal subjects. The prevalences and titers of IgG and IgM anti-β2-glycoprotein I and antiprothrombin antibodies were similar in both groups. Cases were analyzed with respect to the arterial or venous type of thrombosis and to the presence of congenital or acquired risk factors for thrombosis: no statistically significant relationships with the presence of anti-β2glycoprotein I and anti-prothrombin antibodies were found. Our data indicate that anti- β2-glycoprotein I and anti-prothrombin antibodies are not risk factors for thrombosis independent of lupus anticoagulants and anticardiolipin antibodies. Their measurement, therefore, is not warranted in the laboratory screening of patients with arterial and/or venous thrombosis.

Keywords

Antiphospholipid antibodies - anti-β2-glycoprotein I antibodies - antiprothrombin antibodies - thrombosis - casecontrol study

• References

• 1 Tanner D, Levine R, Kittner SJ. Epidemiology of antiphospholipid antibodies and vascular diseases. in Levine SR, Brey RL. (eds). Clinical Approach to Antiphospholipid Antibodies. Boston: Butterworth Heinemann; 2000: 1-18.
• 2 Dizon-Towson D, Branch DW. Obstetric vascular disease in antiphospholipid syndrome. in Levine SR, Brey RL. (eds). Clinical Approach to Antiphospholipid Antibodies. Boston: Butterworth Heinemann; 2000: 81-94.
• 3 Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Out HJ, Harris EN, Vilardell-Torres M, Hughes GRV. The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine 1989; 68: 366-74.
• 4 Alarcon-Segovia D, Deleze M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A review of 500 consecutive cases. Medicine 1989; 68: 353-65.
• 5 Mackie IJ, Donohoe S, Machin SJ. Lupus anticoagulant measurement. in Khamashta MA. (ed). Hughes’ syndrome. London: Springer; 2000: 214-24.
• 6 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle C, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay: Standardization and quantitation of results. Clin Exp Immunol 1985; 62: 739-44.
• 7 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda PJCFriesman, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
• 8 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
• 9 Galli M, Beretta G, Daldossi M, Bevers E, Barbui T. Different anticoagulant properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997; 77: 486-91.
• 10 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris N, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
• 11 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
• 12 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-51.
• 13 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-74.
• 14 Harris EN, Gharavi AE, Hughes GRV. The anticardiolipin assay. in Harris EN, Exner T, Hughes GRV, Asherson RA. (eds). Phospholipid-binding antibodies. Boca Raton: CRC Press; 1991: 175-87.
• 15 Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J Immunol Meth 1991; 143: 223-9.
• 16 Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Van der Valden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 17 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 18 Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001; 113: 544-9.
• 19 Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-9.
• 20 Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men. A nested case-control study. Thromb Haemost 1997; 78: 1178-82.
• 21 Pasquier E, Amiral J, de Saint LMartin, Mottier D. A cross-sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001; 86: 538-42.
• 22 Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/factor syndromes: a primary variant with antibodies to β2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472-81.